TrialsgrambetaRCTs are beautiful

STEP 1

2021

Once-Weekly Semaglutide in Adults with Overweight or Obesity

In 1,961 adults with overweight or obesity without type 2 diabetes, subcutaneous semaglutide 2.4 mg weekly reduced body weight at 68 weeks compared with placebo.

Result

Percent change in body weight
Effect estimate

difference (pp)-12.4P < 0.001

Also reported: ≥15 % loss in 50 % of the semaglutide group.

Original publication
Subtopic
Semaglutide for obesity
Design
Double-blind RCT, 68 weeks
Relevance
Important: one of several pillars.
Source
Wilding JPH, et al. N Engl J Med. 2021;384(11):989-1002.doi 10.1056/NEJMoa2032183

Discussion & critique

Basis of the Wegovy approval. STEP 4 later showed weight regain on withdrawal, framing obesity as a chronic disease requiring continuous therapy.

Discussed in podcasts